When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram |
| |
Authors: | Vimal M Aga |
| |
Institution: | Layton Aging and Alzheimer''s Disease Center, Oregon Health and Science University (OHSU), Portland, OR |
| |
Abstract: | Agitation is a common neuropsychiatric symptom (NPS) in the early and middle stages of Alzheimer's disease (AD) dementia, which is difficult to treat and causes much distress. The U.S. Food and Drug Administration (U.S. FDA) issued black box warnings against the use of antipsychotics in dementia in 2005 and 2008 due to the increased risk of morbidity and mortality, resulting in the reduction in antipsychotic use for treating dementia-related NPS and spurring the quest for safer and more effective pharmacological options. The data favoring the use of citalopram for treating agitation in AD dementia is particularly compelling, and this may be a class effect for all selective serotonin reuptake inhibitors. However, concerns about the cardiac side-effects of citalopram have limited its widespread use for this indication. In this article, available efficacy and safety data for the use of citalopram and escitalopram in treating agitation in AD dementia is reviewed, using a composite case to illustrate key points. Practical recommendations are made to facilitate the use of these medications in routine clinical practice, risk mitigation strategies are discussed and salient issues for future clinical research are emphasized. |
| |
Keywords: | Send correspondence and reprint requests to Vimal M Aga M D Geriatric Psychiatrist Layton Aging and Alzheimer's Disease Center Mail Code CR131 Oregon Health and Science University (OHSU) 3181 S W Sam Jackson Park Road Portland OR 97239-3098 Dementia agitation citalopram escitalopram |
本文献已被 ScienceDirect 等数据库收录! |
|